Ep. 35 - GLP-1 Medications and Breast Cancer Risk: Breaking Down a Landmark New Study

Dr. Tim Sayed walks through a recently accepted study from the Journal of Clinical Oncology Practice showing that GLP-1 medications like Ozempic, Mounjaro, and Zepbound are associated with a significant reduction in breast cancer incidence in overweight women. The paper, led by researchers at the University of Pennsylvania, analyzed electronic health records from roughly 111,000 women ages 45 to 80 with a BMI over 25, comparing breast cancer outcomes between those who had GLP-1 prescriptions and those who did not. The reduction in incidence held across age, race, ethnicity, BMI, breast density, and diabetes status. Dr. Sayed is careful to note what the study is and isn't: it's a retrospective observational cohort, not a randomized controlled trial, and the authors themselves say prospective trials are the necessary next step. He examines the proposed biological mechanisms, how GLP-1 drugs may inhibit cancer cell proliferation and reduce systemic inflammation, and draws a comparison to tamoxifen's established but side-effect-heavy role in breast cancer prevention. He also raises open questions about duration of use, what happens when patients stop, affordability at a population level, and whether pharmaceutical companies have the incentive to pursue formal cancer prevention trials. For patients already navigating GLP-1 treatment or breast health decisions, the findings are worth understanding clearly, even before the full picture is in.Contact Dr. Tim Sayed:Phone: (858) 247-2933Email: [email protected]: timsayedmd.comInstagram: @timsayedmdYouTube: @TimsayedmdFacebook: Tim Sayed MD